ストックスクリーナーアプリを入手
58.25
2.80%
-1.68
アフターアワーズ：
59.30
1.05
+1.80%
Springworks Therapeutics Inc (SWTX) 最新ニュース
SpringWorks Therapeutics' (SWTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Principal Financial Group Inc. Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect - MSN
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Announces Earnings Results, Misses Estimates By $0.38 EPS - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 1-Year HighTime to Buy? - MarketBeat
What the Options Market Tells Us About SpringWorks Therapeutics - Benzinga
Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock - MarketBeat
Insider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 10,672 Shares of Stock - MarketBeat
SpringWorks teams with jewelry designer Jennifer Fisher for desmoid tumors push - MM+M Online
Top 3 Health Care Stocks You May Want To Dump In February - Benzinga
SpringWorks stock hits 52-week high at $61.4 amid growth optimism - Investing.com Nigeria
SpringWorks Therapeutics jumps after results, conference call cancellation - MSN
Sector Update: Health Care Stocks Rise Thursday Afternoon -February 20, 2025 at 01:57 pm EST - Marketscreener.com
SpringWorks stock hits 52-week high at $61.4 amid growth optimism By Investing.com - Investing.com South Africa
SpringWorks Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day - STAT
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics rises as canceled earnings call raises buyout hopes - TradingView
Springworks Therapeutics Q4 Net Loss Narrows -February 20, 2025 at 07:01 am EST - Marketscreener.com
SPRINGWORKS THERAPEUTICS Earnings Results: $SWTX Reports Quarterly Earnings - Nasdaq
Earnings Flash (SWTX) Springworks Therapeutics Posts Q4 Net Loss $-1.04 a Share, vs. FactSet Est of $-0.71 Loss - Marketscreener.com
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
SpringWorks Therapeutics Reports Fourth Quarter and Full - GlobeNewswire
Can SpringWorks' Dual Drug Strategy Transform Its Financial Future? Q4 Results Reveal Key Insights - StockTitan
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownWhat's Next? - MarketBeat
(SWTX) Trading Signals - Stock Traders Daily
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Why SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey
SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors - TipRanks
From Fashion to Fighting Rare Tumors: How This Designer's Personal Battle Could Help Thousands - StockTitan
Here's What Could Help SpringWorks Therapeutics (SWTX) Maintain Its Recent Price Strength - MSN
Wedbush Issues Positive Outlook for SWTX Earnings - MarketBeat
SpringWorks Therapeutics' SWOT analysis: biotech stock faces growth amid losses - Investing.com
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - GlobeNewswire Inc.
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.83 - Defense World
Fiera Capital Corp Decreases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Springworks Therapeutics chief people officer sells shares worth $1.6 million - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells $2,558,400.00 in Stock - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch Sells 175,000 Shares - MarketBeat
Spring Works shares rise on raised price target to $66 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Buy Rating from HC Wainwright - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up on Analyst Upgrade - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Price Target Raised to $65.00 at Evercore ISI - MarketBeat
Badreddin Edris Sells 30,000 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock - MarketBeat
Daniel Pichl Sells 29,750 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock - MarketBeat
SpringWorks therapeutics director Daniel Lynch sells $9.53 million in stock - MSN
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):